Ad Review Board Backs Zicam 'Pre-Cold' Claims

Law360, New York (August 21, 2013, 4:17 PM ET) -- An advertising industry self-regulator on Wednesday ruled that Matrixx Initiatives Inc. did not mislead consumers by overstating the properties of its Zicam cold treatments, rejecting a challenge brought by rival cold remedy maker ProPhase Labs Inc.

The National Advertising Review Board, an appellate unit of the advertising industry’s self-regulatory body, upheld a finding that advertisements describing Zicam as “the pre-cold medicine” and suggesting it can help consumers “go from pre-cold to no cold faster” would not mislead consumers into believing Zicam can prevent colds.

The decision...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers

Required